More sensing stuff....
Patent award....
http://www.pr-inside.com/canadian-patent-granted-for-epinex-novel-r3369318.htm
The Epinex G1A™ Rapid Diabetes Monitoring Index Test is a monthly, point-of-care (POC) immunoassay system for diabetes monitoring and the world's first rapid test to use glycated albumin (GA) as a biomarker. Scientific studies have demonstrated that current monitoring methods for type 2 diabetics (95% of all diabetics), are ineffective due to low compliance rates, physiological interference with test accuracy, and delayed time frames for therapeutic intervention. The G1A™ test is unaffected by factors that impede current monitoring methods and could potentially fulfill the unmet medical need for effective diabetes monitoring for millions of individuals suffering from the disease.
Patent award....
http://www.pr-inside.com/canadian-patent-granted-for-epinex-novel-r3369318.htm
The Epinex G1A™ Rapid Diabetes Monitoring Index Test is a monthly, point-of-care (POC) immunoassay system for diabetes monitoring and the world's first rapid test to use glycated albumin (GA) as a biomarker. Scientific studies have demonstrated that current monitoring methods for type 2 diabetics (95% of all diabetics), are ineffective due to low compliance rates, physiological interference with test accuracy, and delayed time frames for therapeutic intervention. The G1A™ test is unaffected by factors that impede current monitoring methods and could potentially fulfill the unmet medical need for effective diabetes monitoring for millions of individuals suffering from the disease.
